Phase I and pharmacokinetic study of the oral tris-(8-quinolinolato)gallium(III) complex (FFC11, KP46) in patients with solid tumors - a study of the CESAR Central European Society for Anticancer Drug Research - EWIV

Autor:	Andreas Hochhaus, M. Hauses, Margit Gneist, Bernhard K. Keppler, S. Schaad, Michael A. Jakupec, Ulrich Jaehde, C. Salama, Christian Dittrich
Rok vydání:	2005
Předmět:	Cancer Research business.industry chemistry.chemical_element Pharmacology Anticancer drug Tris(8-quinolinolato)gallium (III) Bioavailability Ribonucleotide reductase Oncology Pharmacokinetics chemistry Apoptosis Phase (matter) Medicine Gallium business
Zdroj:	Journal of Clinical Oncology. 23:3205-3205
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2005.23.16_suppl.3205
Popis:	3205 Background: FFC11 is an orally bioavailable gallium complex, which exerts its antitumoral activity via inhibition of ribonucleotide reductase, induction of S phase arrest and apoptosis. In pre...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::9cf99278a78f11c2289e7b903fcf1aa8 https://doi.org/10.1200/jco.2005.23.16_suppl.3205 Zobrazit plný text záznamu